Protagonist Therapeutics, Inc.PTGXNASDAQ
LOADING
|||
R&D Expense Growth Recovery in Progress
Trending higher, below historical average, structural decline.
Left:
||||
Year-over-year research & development expense growth
Latest
14.95%
↓ 61% below average
Average (9y)
38.67%
Historical baseline
Range
High:117.27%
Low:-4.80%
CAGR
-14.1%
Structural decline
| Period | Value |
|---|---|
| 2024 | 14.95% |
| 2023 | -4.80% |
| 2022 | 0.17% |
| 2021 | 65.83% |
| 2020 | 16.89% |
| 2019 | 9.25% |
| 2018 | 28.83% |
| 2017 | 79.66% |
| 2016 | 117.27% |
| 2015 | 58.61% |